•
Mar 31, 2024

Oncology Institute Q1 2024 Earnings Report

The Oncology Institute reported strong revenue growth and reduced SG&A expenses.

Key Takeaways

The Oncology Institute (TOI) reported a 24.2% increase in consolidated revenue, reaching $95 million for Q1 2024. The company signed seven new capitation and value-based contracts across three states. Despite revenue growth, gross profit decreased by 15.1% year-over-year to $12 million. Net loss improved to $19.9 million compared to $30.0 million in the prior year quarter. The company reaffirms its full year 2024 guidance.

Consolidated revenue increased by 24.2% to $95 million compared to the prior year quarter.

Gross profit decreased by 15.1% to $12 million compared to the prior year quarter.

Net loss decreased to $19.9 million compared to $30.0 million for the prior year quarter.

The company signed 7 new capitation and value-based contracts across 3 states.

Total Revenue
$94.7M
Previous year: $76.2M
+24.2%
EPS
-$0.22
Previous year: -$0.33
-33.3%
Clinics
87
Previous year: 76
+14.5%
Lives Under VBC
2M
Previous year: 1.8M
+11.1%
Gross Profit
$12M
Previous year: $14M
-14.3%
Cash and Equivalents
$36.1M
Previous year: $15.3M
+136.4%
Free Cash Flow
-$16.5M
Previous year: -$17.3M
-4.6%
Total Assets
$205M
Previous year: $235M
-12.8%

Oncology Institute

Oncology Institute

Oncology Institute Revenue by Segment

Forward Guidance

TOI reaffirms its full year 2024 guidance.

Revenue & Expenses

Visualization of income flow from segment revenue to net income